1. Home
  2. APLT vs CSTL Comparison

APLT vs CSTL Comparison

Compare APLT & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • CSTL
  • Stock Information
  • Founded
  • APLT 2016
  • CSTL 2007
  • Country
  • APLT United States
  • CSTL United States
  • Employees
  • APLT N/A
  • CSTL N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • CSTL Medical Specialities
  • Sector
  • APLT Health Care
  • CSTL Health Care
  • Exchange
  • APLT Nasdaq
  • CSTL Nasdaq
  • Market Cap
  • APLT 971.6M
  • CSTL 946.1M
  • IPO Year
  • APLT 2019
  • CSTL 2019
  • Fundamental
  • Price
  • APLT $8.69
  • CSTL $28.10
  • Analyst Decision
  • APLT Strong Buy
  • CSTL Strong Buy
  • Analyst Count
  • APLT 5
  • CSTL 7
  • Target Price
  • APLT $12.50
  • CSTL $37.57
  • AVG Volume (30 Days)
  • APLT 1.8M
  • CSTL 457.0K
  • Earning Date
  • APLT 11-07-2024
  • CSTL 11-04-2024
  • Dividend Yield
  • APLT N/A
  • CSTL N/A
  • EPS Growth
  • APLT N/A
  • CSTL N/A
  • EPS
  • APLT N/A
  • CSTL 0.21
  • Revenue
  • APLT N/A
  • CSTL $311,878,000.00
  • Revenue This Year
  • APLT N/A
  • CSTL $49.05
  • Revenue Next Year
  • APLT $3,169.03
  • CSTL N/A
  • P/E Ratio
  • APLT N/A
  • CSTL $133.58
  • Revenue Growth
  • APLT N/A
  • CSTL 62.43
  • 52 Week Low
  • APLT $1.79
  • CSTL $16.97
  • 52 Week High
  • APLT $10.62
  • CSTL $35.84
  • Technical
  • Relative Strength Index (RSI)
  • APLT 46.34
  • CSTL 35.44
  • Support Level
  • APLT $9.44
  • CSTL $30.95
  • Resistance Level
  • APLT $10.62
  • CSTL $34.64
  • Average True Range (ATR)
  • APLT 0.62
  • CSTL 2.15
  • MACD
  • APLT -0.13
  • CSTL -0.56
  • Stochastic Oscillator
  • APLT 14.95
  • CSTL 1.02

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

Share on Social Networks: